Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

6.16
Delayed Data
As of Feb 23
 +0.09 / +1.48%
Today’s Change
4.60
Today|||52-Week Range
11.72
+3.53%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Year
Trend

2013

2014

2015

2016
Revenue and IncomeNet Revenues7.9M44.4M8.7M69.4M
 
 
 
 
 
Cost of Goods Sold624.0K855.0K----
 
 
 
Depreciation And Amortization939.0K545.0K565.0K2.1M
 
 
 
 
 
 
Operating ExpensesGross Income6.3M43.0M----
 
 
 
General Expenses47.0M42.7M45.4M58.8M
 
 
 
 
 
Research And Development34.1M27.7M28.2M37.6M
 
 
 
 
 
Total Operating Expenses48.6M44.1M46.0M60.9M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-40.7M296.0K-37.3M8.5M
 
 
 
 
 
Extraordinary Credit--7.3M0.004.6M
 
 
 
Extraordinary Charge-2.3M-4.2M-2.0M0.00
 
 
 
 
Interest Expense On Debt--0.000.00800.0K
 
 
Other Expenses0.000.000.00-34.0K
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-42.9M3.4M-39.3M12.6M
 
 
 
 
 
Income Taxes-362.0K-989.0K-133.0K-1.8M
 
 
 
 
 
Minority Interest0.000.00-7.0K-73.0K
 
 
 
Net Income-42.6M4.4M-39.1M10.8M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS55.8M68.2M69.7M70.0M
 
 
 
 
 
Shares To Calculate EPS Diluted55.8M68.2M69.7M70.2M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.76$0.06-$0.56$0.15
 
 
 
 
 
EPS Diluted-$0.76$0.06-$0.56$0.15